Anadys Pharmaceuticals announced that dosing has begun in the Phase 2b study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients. Approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.

ANA598 is a non-nucleoside polymerase inhibitor being developed as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection.

For more information call (858) 530-3600 or visit